Compare KKR & Co Inc (KKR) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Pfizer Inc — how do they compare? KKR & Co Inc trades at $111.39 (market cap $99.55B), while Pfizer Inc trades at $26.4 (market cap $149.96B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.54%). Which is the better fit depends on your goals.
| KKR | PFE | |
|---|---|---|
Market Cap | $99.55B | $149.96B |
Sector | Financials | Health |
52-Week High | $149.34 | $28.56 |
52-Week Low | $83.88 | $23.60 |
Enterprise Value | $22.11B | $201.45B |
Dividend Yield | 0.7% | 6.54% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $110.625, up 6.54% today, with strong bullish momentum near its consensus price target of $127.22. Recent earnings beats in Q1 and Q2 2026, alongside a high analyst buy rating of 88.89%, reflect robust operational performance. The company's strategic acquisitions, including Medicover India and Integer Holdings, signal aggressive growth in healthcare and infrastructure sectors.
The outlook for KKR is positive, driven by earnings growth and strategic expansions, but risks include high leverage and market volatility. Upside potential exists if the company maintains its earnings trajectory and executes acquisitions successfully, though investors should monitor debt levels and integration challenges.
Pfizer (PFE) trades at $26.62, down 1.59% with a bullish technical signal. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analyst consensus is mixed with 38% buy ratings and a $27.86 price target. Recent news highlights Pfizer's pipeline developments in oncology and obesity treatments, positioning for future growth despite patent cliff concerns.
Pfizer presents a value opportunity with defensive cash flows and dividend yield, but faces patent expiration risks and competitive pressures. The stock trades below analyst targets with strong institutional support, though margin compression and pipeline execution remain key watchpoints for investors seeking pharmaceutical exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
